An Update on Intracerebral Hemorrhage - A Cohort Study
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 1,000
- Locations
- 1
- Primary Endpoint
- hematoma volume growth at 24 hours
Study Overview
Brief Summary
The intracerebral hemorrhage study is a multicenter , combination of prospective and retrospective observational cohort study led by Dr. Muhammad Junaid Akram, PhD scholar at Chongqing Medical University. Prof Dr. Qi Li will be the senior consultant for the study. The study will be focusing on natural history, epidemiological , radiological, rehabilitative and clinical aspects as well as the effect of various treatments on the hemorrhagic patients.
The study related data of the patients diagnosed with intracerebral hemorrhage will be collected in prospective and retrospective ways. The prognostic data for the patients will be assembled and collected via using different outcome measures at different points of time.
Detailed Description
The study will be used to address the several key issues related to intracerebral hemorrhage. The demographics, scores based upon disease severity , mRS, GCS, NIHSS scores will be recorded at baseline and in the prospective and retrospective ways. The data obtained from the registered patients will be used for future use , critical review by expert neurologists, neurorehabilitative experts for further use and review.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age > 18 years Patients willing to participate via signing a consent form' Patients diagnosed with CT-Confirmed spontaneous intracerebral hemorrhage (ICH) Patients willing to participate in the follow up assessment
Exclusion Criteria
- •Not willing to participate Secondary ICH to hemorrhagic infarction or tumor bleeding etc. Traumatic ICH
Outcomes
Primary Outcomes
hematoma volume growth at 24 hours
Time Frame: 24 hours
To assess early hematoma volume growth at 24 hours
Secondary Outcomes
- Perihematomal edema volume measurement at 24 hours(24 hours)
- Perihematomal edema volume measurement at 48 hours(48 hours)
- Perihematomal edema volume measurement at 72 hours(72 hours)
- Major thrombotic events(2 weeks)
- Functional outcome at 3 months assessed by modified Rankin Scale(3 months)
- Early neurological deterioration assessed by NIHSS score at 24 hours(24 hours)
- Early neurological deterioration assessed by NIHSS score at 48 hours(48 hours)
- Intraventricular hemorrhage growth(24 hours)
- Early neurological deterioration assessed by NIHSS score at 72 hours(72 hours)
Investigators
Dr. Muhammad Junaid Akram
Dr. Muhammad Junaid Akram
Shifa Clinical Research Center